ReviewEndocrine2016
Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.
Review in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.Nature reviews. Endocrinology · 2024Guideline
- Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management.Pituitary · 2019Pooled it
- Article
- Thyrotropin/growth hormone co-secreting pituitary adenoma with pancytopenia: a case report.Journal of medical case reports · 2026Article
- Differential diagnosis of familial dysalbuminemic hyperthyroxinemia , RTH, and TSHomas: A single-center retrospective analysis.Endocrine · 2026Article
- Case Report: Development of a thyrotropinoma in a patient with thyroid hemiagenesis.Frontiers in endocrinology · 2026Article
- Long-term surgical outcomes in TSH-secreting pituitary adenomas: the hidden burden of asymptomatic hyperthyroidism.Endocrine · 2025Article
- Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.Immunity, inflammation and disease · 2024Review
- Gamma knife radiosurgery is effective in patients with thyrotropin-secreting pituitary adenomas.Journal of endocrinological investigation · 2024Article
- Growth hormone-secreting pituitary adenoma combined with Graves' disease: retrospective case series and literature review.Endocrine connections · 2024Article
- Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Central hyperthyroidism due to an ectopic TSH-secreting pituitary tumor: a case report and literature review.Frontiers in endocrinology · 2024Review
- The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.Cancers · 2023Review
- Gonadotropin-secreting and thyrotropin-secreting pituitary adenomas: A single-center experience.Archives of endocrinology and metabolism · 2023Article
- Familial dysalbuminemic hyperthyroxinemia combined with Graves' disease: a rare case report.BMC endocrine disorders · 2023Article
- [Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients].Problemy endokrinologii · 2023Article
- The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study.BMC endocrine disorders · 2023Article
- Case report: A rare case of thyrotropin-secreting pituitary macroadenoma with diffuse calcification presenting with hyperthyroidism and literature review.Frontiers in oncology · 2023Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inappropriate secretion of TSH was first described in 1960 in a patient with evidence of hyperthyroidism and expanded sella on imaging. It was later found that a type of pituitary adenoma that secretes TSH (thyrotropinoma) was the underlying cause. The objective of the present review article is to summarize data on the epidemiology, pathogenesis, diagnosis, and management of thyrotropinomas. The prevalence of thyrotropinomas is lower than that of other pituitary adenomas. Early diagnosis is now possible thanks to the availability of magnetic resonance imaging and sensitive laboratory assays. As a corollary, many patients now present earlier in the course of their disease and have smaller tumors at the time of diagnosis. Treatment also has evolved over time. Transsphenoidal surgery is still considered definitive therapy. Meanwhile, radiation therapy, including radiosurgery, is effective in achieving tumor control in the majority of patients. In the past, radiation therapy was used as second line treatment in patients with residual or recurrent tumor after surgery. However, the availability of somatostatin analogs, which can lead to normalization of thyroid function as well as shrink these tumors, has led to an increase in the role of medical therapy in patients who are not in remission after pituitary surgery. In addition, dopamine agonists have shown some efficacy in the management of these tumors. Better understanding of the molecular pathogenesis of thyrotropinomas may lead to rationally designed therapies for patients with thyrotropinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.